NICEVIVA
DRUG INTERACTION RECORDED 1 Prescription Drug Interaction(s) Reported — Review the pharmacokinetic interaction matrix below before use.
Pharmacokinetic Alert
MONOGRAPH SPEC LATEST 2026

Brewer's Yeast (Medicinal Yeast · Saccharomyces cerevisiae)

SKIN HAIR · Evidence Monograph

Brewer's Yeast (Medicinal Yeast · Saccharomyces cerevisiae) is an evidence-graded skin hair monograph evaluated across 20 peer-reviewed PubMed studies (0 meta-analyses, 0 systematic reviews, and 0 randomized controlled trials, encompassing n = 216 cumulative participants). Current clinical evidence is rated GRADE Low (2.0 / 4.0) for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

Evidence Grade (GRADE) Low (2.0 / 4.0)
Indexed PubMed Studies 20 Studies
Meta-Analyses · Reviews 0 Meta · 0 Systematic Reviews
Randomized Trials (RCT) 0 RCTs (0 Double-Blind)
Cumulative Participants n = 216
Reported Trial Dosages 0.05 g/day · 0.08 g/day
Trial Duration Range 12 weeks · 4 days · 18 weeks
Reading Time ~10 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support (supported by 20 indexed PubMed studies, GRADE Low).
  2. 02 Adults matching clinical trial dosing protocols (0.05 g/day · 0.08 g/day) over a structured 12 weeks evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Clinically Standardized Formulation
Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.
Dose Adjustment Signal: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
With Breakfast or Lunch
Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
alopecia (PubMed clinical endpoint)
hair (PubMed clinical endpoint)
telogen effluvium (PubMed clinical endpoint)
01

What Is Brewer's Yeast (Medicinal Yeast · Saccharomyces cerevisiae) & Why Does Form Matter?

Brewer's Yeast (Medicinal Yeast · Saccharomyces cerevisiae) is classified under SKIN HAIR and has been investigated across 20 peer-reviewed PubMed publications for its role in targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (0.05 g/day, 0.08 g/day).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Brewer's Yeast (Medicinal Yeast · Saccharomyces cerevisiae) frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (0 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Brewer's Yeast (Medicinal Yeast · Saccharomyces cerevisiae) acts on pathways governing targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Brewer's Yeast (Medicinal Yeast · Saccharomyces cerevisiae) an overall evidence rating of GRADE Low (2.0 / 4.0) based on 20 PubMed studies: 0 meta-analyses, 0 systematic reviews, and 0 randomized controlled trials (0 double-blind, n = 216 total participants).

Representative peer-reviewed findings include: • PMID:42938364 (2026) — "Ectopic Expression of AsDof6.5 from Oat (Avena sativa L.) Enhances Low Nitrogen Tolerance in Transgenic Arabidopsis thaliana." (Physiological assays further demonstrated that AsDof6.5 overexpression efficiently reduced malondialdehyde (MDA) accumulation while simultaneously preserving soluble protein (SP) levels.) • PMID:42796811 (2026) — "Tri-Culture Fermentation of Neem (Azadirachta indica) Leaves Induces Phytochemical Remodeling and Enhances Multi-Target Bioactivities Relevant to Androgenetic Alopecia." (Juss., Meliaceae) leaves, a phenolic-) • PMID:42737762 (2026) — "Mixed-Culture Fermentation of Coffee Pulp Induces Metabolomic Changes and Enhances Multi-Target Bioactivity Relevant to Androgenetic Alopecia." (This study investigated whether fermentation with Saccharomyces cerevisiae, Lactobacillus plantarum, or their mixed culture could remodel c)

05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Clinically Standardized Formulation. Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 0.05 g/day · 0.08 g/day over 12 weeks · 4 days · 18 weeks · 30 days. Optimal timing window: PM 12:30 · With Breakfast or Lunch (Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.

Adjustment & Discontinuation Signals: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.

07

Prescription Drug Interactions & Contraindications

• [MODERATE] MAO / (Allopurinol ): Pharmacokinetic or pharmacodynamic interaction reported in clinical literature (PMID:3974680). Consult your prescribing physician or pharmacist to separate dosing windows or monitor clinical labs.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · With Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (0.05 g/day · 0.08 g/day) and re-evaluate efficacy after 12 weeks.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist before use if taking MAO / (Allopurinol ).
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (20 Studies)

01
CLINICAL STUDY Genes (2026) PMID: 42938364 ↗
Ectopic Expression of AsDof6.5 from Oat (Avena sativa L.) Enhances Low Nitrogen Tolerance in Transgenic Arabidopsis thaliana.
Clinical Trial Synthesis 2026 Clinical Study published in Genes. Key conclusion: Physiological assays further demonstrated that AsDof6.5 overexpression efficiently reduced malondialdehyde (MDA) accumulation while simultaneously preserving soluble protein (SP) levels.
View Original PubMed Abstract ↓

BACKGROUND: Oat (Avena sativa L.) is a vital forage and cereal crop widely cultivated on the Qinghai-Tibet Plateau, known for its outstanding adaptability to barren soils. Nitrogen (N) is a critical macronutrient, and the excessive application of N fertilizers has triggered severe ecological crises. Identifying key genes regulating adaptation to low N stress is essential for breeding N-efficient oat varieties. The DNA-binding with one finger (Dof) transcription factors play crucial roles in plant stress responses, but their precise molecular mechanisms in oat N-deficiency adaptation remain largely unknown. RESULTS: In this study, we conducted a comprehensive genome-wide identification and unveiled 54 AsDof genes in the oat genome. Phylogenetic, synteny, and promoter analyses revealed their high evolutionary conservation and complex potential roles in stress networks. Transcriptome profiling under low N stress pinpointed AsDof6.5 as a potential candidate. Ectopic expression of AsDof6.5 in Arabidopsis thaliana significantly enhanced plant adaptation to low N. This was morphologically manifested as enhanced primary root elongation, increased root hair number, and significantly higher fresh weight under N-deprived conditions. Physiological assays further demonstrated that AsDof6.5 overexpression efficiently reduced malondialdehyde (MDA) accumulation while simultaneously preserving soluble protein (SP) levels. Yeast two-hybrid (Y2H) and bimolecular fluorescence complementation (BiFC) assays demonstrated that AsDof6.5 has the potential to physicall

02
CLINICAL STUDY Plants (Basel, Switzerland) (2026) PMID: 42796811 ↗
Tri-Culture Fermentation of Neem (Azadirachta indica) Leaves Induces Phytochemical Remodeling and Enhances Multi-Target Bioactivities Relevant to Androgenetic Alopecia.
Clinical Trial Synthesis 2026 Clinical Study published in Plants (Basel, Switzerland). Key conclusion: Juss., Meliaceae) leaves, a phenolic-
View Original PubMed Abstract ↓

Androgenetic alopecia (AGA) involves dihydrotestosterone-driven follicular miniaturization compounded by oxidative stress and perifollicular inflammation, while current pharmacotherapies remain limited by adverse effects. Neem (Azadirachta indica A. Juss., Meliaceae) leaves, a phenolic-

03
CLINICAL STUDY International journal of molecular sciences (2026) PMID: 42737762 ↗
Mixed-Culture Fermentation of Coffee Pulp Induces Metabolomic Changes and Enhances Multi-Target Bioactivity Relevant to Androgenetic Alopecia.
Clinical Trial Synthesis 2026 Clinical Study published in International journal of molecular sciences. Key conclusion: This study investigated whether fermentation with Saccharomyces cerevisiae, Lactobacillus plantarum, or their mixed culture could remodel c
View Original PubMed Abstract ↓

Androgenetic alopecia (AGA), the most common form of hair loss, is driven by dihydrotestosterone-mediated follicular miniaturization, oxidative stress, and perifollicular inflammation, requiring multi-target intervention. Coffee pulp is an abundant coffee-processing by-product and a potential source of value-added bioactives relevant to AGA. This study investigated whether fermentation with Saccharomyces cerevisiae, Lactobacillus plantarum, or their mixed culture could remodel c

04
CLINICAL STUDY Journal of cutaneous pathology (2026) PMID: 42198905 ↗
Transverse Histological Analysis of Scalp Seborrheic Dermatitis: A Novel Perspective.
Clinical Trial Synthesis 2026 Clinical Study published in Journal of cutaneous pathology involving n = 35 participants; statistical significance reported at p = 0.05. Key conclusion: CONCLUSION: The findings emphasize that the absence of sebaceous gland atrophy is a useful criterion in the differentiation of seborrheic dermatitis from psoriasis of the scalp.
View Original PubMed Abstract ↓

BACKGROUND: Seborrheic dermatitis is a chronic inflammatory disease affecting seborrheic areas of the skin, including the scalp. It is often confused with scalp psoriasis due to similar clinical and histopathological features. OBJECTIVE: This study described microscopic changes in the pilosebaceous unit in seborrheic dermatitis (SDS) using cross-sectional histological sections in order to improve diagnostic accuracy in differentiating SDS from scalp psoriasis and early-stage alopecia. METHODS: This study included 35 men aged 18-65 diagnosed with SDS (both mild and severe cases). Scalp biopsies were obtained and analyzed for 35 microscopic parameters, including quantitative and qualitative variables, and compared with the data of scalp psoriasis from a previous study. RESULTS: Among 35 scalp biopsies from seborrheic dermatitis (SDS) cases, no significant histological differences were observed between mild and severe forms. Sebaceous gland atrophy was absent in SDS but present in 40% of 22 psoriasis cases, which also showed significantly smaller gland size (0.22 vs. 0.51 mm; p < 0.05). Perifollicular inflammation and fibrosis were common in SDS, while Malassezia yeasts and Demodex mites were rarely identified. LIMITATIONS: The small sample size and lack of longitudinal follow-up limit the generalizability of the results. Additionally, only scalp biopsies were analyzed, excluding other affected areas. CONCLUSION: The findings emphasize that the absence of sebaceous gland atrophy is a useful criterion in the differentiation of seborrheic dermatitis from psoriasis of the scalp. They also highlight the diagnostic complexity of SDS with histologi

05
CLINICAL STUDY Journal of cosmetic dermatology (2026) PMID: 42144810 ↗
Effectiveness, Tolerability, and Acceptance of a Food Supplement in the Management of Non-Illness-Related Hair Loss and Thinning.
Clinical Trial Synthesis 2026 Clinical Study published in Journal of cosmetic dermatology involving n = 109 participants; statistical significance reported at p = 0.001. Key conclusion: CONCLUSIONS: The combination of millet extract, pantothenic acid, L-cystine, and biotin was associated with reduced hair loss, improv
View Original PubMed Abstract ↓

BACKGROUND: Diffuse hair loss and shedding is often managed with food supplements, yet evidence for ingredient combinations is limited. Our exploratory study evaluated a nutritional supplement (Priorin capsules, Bayer) containing millet extract, pantothenic acid (vitamin B5), L-cystine, and biotin (vitamin B7) in healthy subjects with light diffuse hair loss. METHODS: In this open-label, intra-individual, multicenter study, subjects with non-illness-related, light diffuse hair loss used the product (two capsules/day) for 12 weeks. Endpoints included objective measurements of hair density, hair growth coefficient, and hair loss (phototrichogram), subjective evaluations of hair appearance, beauty and volume (hairdresser-rated), consumer perception and acceptance, and tolerability. RESULTS: In 112 subjects (mean age 32 ± 1 years; 93.8% female), hair density (n = 109) and the proportion of hairs in the anagen phase increased significantly, while the telogen proportion decreased (p < 0.001, week 12 vs. baseline). Hair loss had declined by 59% at week 12 (p < 0.001). Significant improvements in the hairdresser-rated hair quality and appearance parameters (shine, softness/elasticity, strength, smoothness, dryness, vitality, volume) were observed (p < 0.001). From week 2, subjects reported progressive improvement in appearance, growth, and slowing of hair loss. At week 12, 90% of subjects perceived improved hair appearance and growth, 85% reported slowing down of hair loss, and 82% were satisfied with the overall hair improvements with treatment. The supplement was generally well tolerated. CONCLUSIONS: The combination of millet extract, pantothenic acid, L-cystine, and biotin was associated with reduced hair loss, improv

06
CLINICAL STUDY Clinical, cosmetic and investigational dermatology (2026) PMID: 42039771 ↗
Alterations in the Hair Follicle Bacteriome and Mycobiome in Androgenetic Alopecia: A Cross-Sectional Study of 72 Patients and 24 Healthy Controls.
Clinical Trial Synthesis 2026 Clinical Study published in Clinical, cosmetic and investigational dermatology involving n = 72 participants. Key conclusion: Given that the hair follicle harbors a distinct microbiota which may modulate local immune responses, this study aimed to comprehensively profile the bacterial and fungal microbiome within the deep hair follicles of AGA patients versus healthy controls, and to evaluate the influe
View Original PubMed Abstract ↓

PURPOSE: Androgenetic alopecia (AGA) is characterized by perifollicular micro-inflammation, although its precise trigger remains elusive. Given that the hair follicle harbors a distinct microbiota which may modulate local immune responses, this study aimed to comprehensively profile the bacterial and fungal microbiome within the deep hair follicles of AGA patients versus healthy controls, and to evaluate the influence of disease severity, age, sex, and geographical environment. PATIENTS AND METHODS: We recru

07
CLINICAL STUDY Molecules (Basel, Switzerland) (2026) PMID: 41976212 ↗
Multifunctional Bioactivity of Saccharomyces cerevisiae Extracellular Vesicle in Hair Follicle-Related Cellular Models.
Clinical Trial Synthesis 2026 Clinical Study published in Molecules (Basel, Switzerland). Key conclusion: Extracellular vesicles (EVs) derived from microbial sources, including beer yeast (Saccharomyces cerevisiae), have recently attracted increasing attention as bioactive nanostructures with potential biomedical and cosmetic applications.
View Original PubMed Abstract ↓

Extracellular vesicles (EVs) derived from microbial sources, including beer yeast (Saccharomyces cerevisiae), have recently attracted increasing attention as bioactive nanostructures with potential biomedical and cosmetic applications. In this study, EVs were isolated from Saccharomyces cerevisiae (beer yeast) using an electrokinetic ion-binding filtration system, followed by tangential flow filtration (TFF)-based buffer exchange. Their physicochemical characteristics and hair follicle-related biological activities were systematically evaluated. Nanoparticle tracking analysis demonstrated a mean particle size within the typical EV range, and zeta potential analysis confirmed a negatively charged surface. Cryo-transmission electron microscopy further verified the presence of lipid bilayer-enclosed nanovesicles. Biological activity was assessed in human dermal papilla cells, keratinocytes, and dermal fibroblasts, which collectively represent key components of the hair follicle microenvironment. At non-cytotoxic concentrations, yeast-derived EVs enhanced dermal papilla cell proliferation and promoted keratinocyte migration. The EVs attenuated pro-inflammatory cytokine expression under stimulated conditions and upregulated collagen-related gene expression in dermal fibroblasts. In addition, measurable antioxidant activity was observed. Collectively, these findings indicate that S. cerevisiae-derived extracellular vesicles exhibit multifunctional bioactivity relevant to the regulation of hair follicle-associated cellular processes. This study supports the potential of microbial EVs as scalable bioactive platforms for modulating hair follicle microenvironmental homeostasis.

08
CLINICAL STUDY International journal of dermatology (2026) PMID: 41823643 ↗
Scalp Microbiome Alterations in Androgenetic Alopecia: Patterns and Emerging Mechanistic Insights.
Clinical Trial Synthesis 2026 Clinical Study published in International journal of dermatology. Key conclusion: Increases in Malassezia and reductions in Lawsonella and Corynebacterium have also been described, though results are less consistent across studies, while Staphylococcus displays variable patterns.
View Original PubMed Abstract ↓

Androgenetic alopecia (AGA), the most common cause of hair loss in men and women, involves progressive follicular miniaturization and reduced hair density. Emerging evidence implicates the scalp microbiome as a potential modifier of this process. Preliminary evidence suggests alterations in microbial communities in patients with AGA compared to the general population, with the most robust finding being an enrichment of Cutibacterium acnes, particularly in males. Increases in Malassezia and reductions in Lawsonella and Corynebacterium have also been described, though results are less consistent across studies, while Staphylococcus displays variable patterns. These microbial shifts parallel alterations in scalp sebum composition, such as elevated triglycerides and palmitic acid, that may favor growth of lipophilic microbes. Mechanistic insights from in vitro studies and related inflammatory skin conditions indicate that C. acnes and Malassezia spp. are capable of generating free fatty acids and activating innate immune pathways, such as TLR2- and NLRP3-associated signaling, leading to pro-inflammatory cytokine production, potentially contributing to follicular stem cell apoptosis and hair follicle miniaturization. Although findings remain heterogenous, emerging evidence suggests microbial-lipid-immune interactions may contribute to AGA pathogenesis, providing a rationale for exploring treatments like ketoconazole or other lipid-modulating interventions. © 2026 The Author(s). International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology.

09
CLINICAL STUDY Plant science (2026) PMID: 41763272 ↗
RlTTG1 isolated from Rosa laevigata Michx. regulates trichome development and stress response in transgenic Arabidopsis.
Clinical Trial Synthesis 2026 Clinical Study published in Plant science. Key conclusion: A gene closely related to prickle development was selected for functional research, which was named TRANSPARENT TESTA GLABRA 1 (TTG1).
View Original PubMed Abstract ↓

Rosa laevigata Michx. (R. laevigata) is an important horticultural plant with strong drought resistance and ornamental value. Its fruit can be used as medicine, but its fruits and stems are covered with dense prickles, which leads to difficulty for cultivation. The molecular mechanism of prickle development in R. laevigata is still unknown. In the present study, eighty-one prickle-related genes were found by transcriptome sequencing. A gene closely related to prickle development was selected for functional research, which was named TRANSPARENT TESTA GLABRA 1 (TTG1).

10
CLINICAL STUDY Antioxidants (Basel, Switzerland) (2025) PMID: 41462701 ↗
Fermented Yeast Complex Extract Promotes Hair Regrowth by Decreasing Oxidative Stress.
Clinical Trial Synthesis 2025 Clinical Study published in Antioxidants (Basel, Switzerland). Key conclusion: Importantly, FYCE also attenuated the activation of the NLRP3 inflammasome, as evidenced by the decreased expression levels of its molecular components.
View Original PubMed Abstract ↓

Hair growth is orchestrated by a complex cycle comprising the anagen, catagen, telogen, and exogen phases that are largely regulated by dermal papilla cells (DPCs). The disruption of oxidative balance and inflammation impairs follicle function and regeneration. Fermented yeast complex extract (FYCE) is a bioactive material derived from enzymatically hydrolyzed yeast and collagen substrates through a two-step fermentation with Lactobacillus brevis and Lactobacillus plantarum, enriched in antioxidant amino acids such as γ-aminobutyric acid (GABA) and L-alanine. In this study, we evaluated the effect of FYCE on hair regrowth, with a focus on its modulation of oxidative stress and inflammatory pathways in hydrogen peroxide (H2O2)-treated DPCs. FYCE treatment significantly enhanced NRF2 expression (3.2-fold compared to H2O2-treated DPCs), a central transcription factor controlling antioxidant defense, and concomitantly suppressed NF-κB activity (0.6-fold compared to H2O2-treated DPCs), a key mediator of inflammation. Importantly, FYCE also attenuated the activation of the NLRP3 inflammasome, as evidenced by the decreased expression levels of its molecular components. Comp

RELATED MONOGRAPHS

Related Monographs in This Category